✨ Your Portfolio is fetched and updated from zerodha.
Small Business Support

Sun Pharma Advanced Research Company Ltd.

SPARC

Market Cap
₹4,959 Cr.
P/E
0.00

Sun Pharma Advanced Research Company Ltd.

  • Sun Pharma Adv. Res
  • Dishman Carbogen Amc
  • Zenotech Laboratorie
  • TJI Pharma - Small Cap
FAQs on Sun Pharma Advanced Research Company Ltd. Shareprice

Sun Pharma Adv. Res has given lower returns compared to its competitors.
Sun Pharma Adv. Res has grown at ~-13.54% over the last 7yrs while peers have grown at a median rate of 1.03%

There is insufficient historical data to gauge this.
Latest PE of Sun Pharma Adv. Res is 0

View FAQ's On Business
Growth Table
  • Sun Pharma Advanced Research Company Ltd.
  • Dishman Carbogen Amc
  • Zenotech Laboratorie
Balance Sheet
  • Sun Pharma Advanced Research Company Ltd.
  • Dishman Carbogen Amc
  • Zenotech Laboratorie
Balance Sheet Snapshot
No data available.
Fund Flow Analysis
  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
*Data is as of latest FY end
Profit & Loss
  • Sun Pharma Advanced Research Company Ltd.
  • Dishman Carbogen Amc
  • Zenotech Laboratorie
Cash Flow
  • Sun Pharma Advanced Research Company Ltd.
  • Dishman Carbogen Amc
  • Zenotech Laboratorie
Cash Flow Analysis
  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
Ratios
= Dominant Factor
  • Sun Pharma Advanced Research Company Ltd.
  • Dishman Carbogen Amc
  • Zenotech Laboratorie
Quarterly Results
  • Sun Pharma Advanced Research Company Ltd.
  • Dishman Carbogen Amc
  • Zenotech Laboratorie
Reverse DCF
locked
Cr
locked
5 YEAR
locked 5
10 YEAR
locked 10
20 YEAR
locked 20
Implied Growth Rate over a 5 year period*
Implied Growth Rate over a 10 year period*
Implied Growth Rate over a 20 year period*
*Implied Growth calculated using Newton-Rhapson method.
Learn how to use Reverse DCF
FAQs on Sun Pharma Advanced Research Company Ltd. Financials

Balance sheet of Sun Pharma Adv. Res is strong.
It shouldn't have solvency or liquidity issues.

Yes, The debt of Sun Pharma Adv. Res is increasing.
Latest debt of Sun Pharma Adv. Res is ₹83.08 Crs as of Sep-24.
This is greater than Mar-24 when it was -₹263.66 Crs.

No, profit is decreasing.
The profit of Sun Pharma Adv. Res is -₹388.53 Crs for TTM, -₹387.21 Crs for Mar 2024 and -₹222.58 Crs for Mar 2023.

The company seems to be paying a very low dividend.
Investors need to see where the company is allocating its profits.
Sun Pharma Adv. Res latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%

Companies resources are allocated to majorly productive assets like Plant & Machinery and unproductive assets like Capital Work in Progress, Inventory, Accounts Receivable, Short Term Loans & Advances

View FAQ's On Shareholding
Ideas Dashboard
Timeline
Watchlist
Portfolio
Alerts
Research
Stock Screener
Market
Raw Material
Data feed provided by Accord Fintech